<DOC>
	<DOC>NCT00231075</DOC>
	<brief_summary>Safety and Efficacy of Paraplatin in combination with Taxol in patients of 70 years or older with epithelial ovary cancer F.I.G.O. stages III and IV.</brief_summary>
	<brief_title>Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IV</brief_title>
	<detailed_description>The Main objective of this study is to evaluate the faisibility of chemotherapy with Paraplatin in combination with Taxol in patients of 70 years or older with epithelial ovary cancer F.I.G.O. stages III and IV and to determine principal predictive factors of this feasibility.</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histological or cytological proven diagnosis of epithelial ovary cancer F.I.G.O stages III or IV (when only cytological proven diagnosis is available: malignant cells and pelvis tumoral mass and increased CA125 must be diagnosed simultaneously) Patient aged &gt; 70 years Neutrophil polynuclears &gt; 1500/mm3 and Platelets &gt; 100 000/mm3 No clinical icterus Life expectancy of at least 3 months Previous diagnosis of malignancy Previous chemotherapy treatment Previous radiotherapy Hypersensitivity to products containing Cremophore EL Hepatic values: bilirubine &gt; 2*LSN, SGOTSGPT &gt; 2*LSN and/or Alkalin phosphatase &gt; 3*LSN Myocardiopathy with arrhythmia</criteria>
	<gender>Female</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Epithelial ovary cancer F.I.G.O. stages III or IV</keyword>
	<keyword>70 years or older</keyword>
</DOC>